Ó³»­´«Ã½

Skip to main content
Home

Top menu

  • Careers
Search
  • Ó³»­´«Ã½
      1. This is Ó³»­´«Ã½ Learn about our mission, our values, our history, and partner institutions.
      2. Our impact Discover the impact of our research on human health.
      3. People Meet our members, staff scientists, fellows, leadership, and other Ó³»­´«Ã½ies.
      4. Join Ó³»­´«Ã½ Find out how to join the Ó³»­´«Ã½ as an employee or associate member.
      5. Contact us Find our contact information, directions to our buildings, and directory.
  • Research
      1. Disease areas Ó³»­´«Ã½ brings people together to advance the understanding and treatment of disease.
        1. Items Wpapp col
          • Brain Health
          • Cancer
          • Cardiovascular disease
          • Chronic disease
          • Diabetes
          • Infectious disease and microbiome
          • Kidney disease
          • Obesity
          • Rare disease
      2. Research areas Through programs spanning genetics, biology, artificial intelligence (AI), and therapeutic development, Ó³»­´«Ã½ researchers are making discoveries that drive biomedical science forward.
        1. Items Wpapp col
          • AI and machine learning
          • Chemical biology and therapeutics science
          • Genome regulation, cellular circuitry, and epigenomics
          • Immunology
          • Medical and population genetics
          • Metabolism
      3. Technology platforms Ó³»­´«Ã½'s technology platforms create, adapt, and scale technologies to accelerate science at the institute and beyond.
        1. Items Wpapp col
          • Data sciences
          • Drug discovery
          • Genetic perturbation
          • Genomics / Ó³»­´«Ã½ Clinical Labs
          • Imaging
          • Metabolomics
          • Proteomics
          • Spatial technologies
      4. Science
        1. Patient-partnered research Patients partner with our scientists to accelerate the pace of discovery and find better treatments.
        2. Partnering and licensing We work closely with pharmaceutical, biotech, and technology partners to accelerate the translation of our discoveries.
        3. Publications A catalog of scientific papers published by our members and staff scientists.
        4. Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators.
        5. Collaborations and consortia We join with institutions and scientists the world over to address foundational challenges in science and health.
  • Centers
      1. Carlos Slim Center for Health Research The Slim Center aims to bring the benefits of genomics-driven medicine to Latin America, gleaning new insights into diseases with relevance to the region.
      2. Gerstner Center for Cancer Diagnostics The Gerstner Center is developing next-generation diagnostic technology for cancer detection and tracking disease progression.
      3. Klarman Cell Observatory The Klarman Cell Observatory is systematically defining mammalian cellular circuits, how they work together to create tissues and organs, and are perturbed to cause disease.
      4. Merkin Institute for Transformative Technologies in Healthcare The Merkin Institute is supporting early-stage ideas aimed at advancing powerful technological approaches for improving how we understand and treat disease.
      5. Novo Nordisk Foundation Center for Genomic Mechanisms of Disease This center is developing new paradigms and technologies to scale the discovery of biological mechanisms of common, complex diseases, by facilitating close collaborations between the Ó³»­´«Ã½ and the Danish research community.
      6. Eric and Wendy Schmidt Center The EWSC is catalyzing a new field of interdisciplinary research at the intersection of data science and life science, aimed at improving human health.
      7. Stanley Center for Psychiatric Research The Stanley Center aims to reduce the burden of serious mental illness by contributing new insights into pathogenesis, identifying biomarkers, and paving the way toward new treatments.
  • Education and outreach
      1. Art and science connection Explore the connection between art and science and how we bring together artists and Ó³»­´«Ã½ scientists through our artist-in-residence program, gallery exhibitions, and ongoing public conversations.
      2. Ó³»­´«Ã½ Discovery Center Visit our free public educational space that showcases how researchers at the Ó³»­´«Ã½ and their colleagues around the world seek to understand and treat human disease.
      3. Learning resources Access free classroom materials and more for STEM educators, parents, students, tutors, and others.
      4. Public programs Discover remarkable stories of scientific progress, and explore the intersections of science, medicine, and society.
      5. Student opportunities Learn about Ó³»­´«Ã½'s mentored research offerings for high school students, college students, and recent college graduates.
      6. Visit Ó³»­´«Ã½ Come see what Ó³»­´«Ã½ is all about.
  • News
      1. News and insights Learn about breakthroughs from Ó³»­´«Ã½ scientists.
        1. Column
      2. Press room Contact our media relations team.
        1. Column
      3. Sign up for our newsletter Receive regular updates on Ó³»­´«Ã½ news, research and community.
  • Careers
  • Search
is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice.
Fink EC, McConkey M, Adams DN, et al. is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood. 2018;132(14):1535-1544. doi:10.1182/blood-2018-05-852798
Read more
Phytol: A review of biomedical activities.
Islam MT, Ali ES, Uddin SJ, et al. Phytol: A review of biomedical activities. Food Chem Toxicol. 2018;121:82-94. doi:10.1016/j.fct.2018.08.032
Read more
Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells.
Kozono S, Lin YM, Seo HS, et al. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nat Commun. 2018;9(1):3069. doi:10.1038/s41467-018-05402-2
Read more
Targeted therapy for fusion-driven high-risk acute leukemia.
Pikman Y, Stegmaier K. Targeted therapy for fusion-driven high-risk acute leukemia. Blood. 2018;132(12):1241-1247. doi:10.1182/blood-2018-04-784157
Read more
Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis.
Tang YC, Yuwen H, Wang K, et al. Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis. Cancer Res. 2017;77(19):5272-5286. doi:10.1158/0008-5472.CAN-17-0049
Read more
Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.
Shaw AT, Winslow MM, Magendantz M, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A. 2011;108(21):8773-8. doi:10.1073/pnas.1105941108
Read more
A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera.
Jack S, Madhivanan K, Ramadesikan S, et al. A novel, safe, fast and efficient treatment for Her2-positive and negative bladder cancer utilizing an EGF-anthrax toxin chimera. Int J Cancer. 2020;146(2):449-460. doi:10.1002/ijc.32719
Read more
Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action.
McFarland JM, Paolella BR, Warren A, et al. Multiplexed single-cell transcriptional response profiling to define cancer vulnerabilities and therapeutic mechanism of action. Nat Commun. 2020;11(1):4296. doi:10.1038/s41467-020-17440-w
Read more
Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors.
Edelman G, Rodon J, Lager J, et al. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist. 2018;23(4):401-e38. doi:10.1634/theoncologist.2017-0691
Read more
RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines.
Basu A, Mitra R, Liu H, Schreiber SL, Clemons PA. RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines. Bioinformatics. 2018;34(19):3332-3339. doi:10.1093/bioinformatics/bty199
Read more

Pagination

  • Previous page ‹â¶Ä¹
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Next page ›â¶Äº

Address

Merkin Building
415 Main St.
Cambridge, MA 02142

Follow Us

Home

Sign up for our newsletter

Did you know?

In March of 2020, Ó³»­´«Ã½ converted a clinical genetics processing lab into a large-scale COVID-19 testing facility in less than two weeks.

We've screened more than 1,275 cancer cell lines as part of the Cancer Dependency Map (DepMap).

Ó³»­´«Ã½ Genomics Platform sequences a whole human genome every four minutes.

More than 11,000 individuals living with cancer in the United States and Canada have partnered with Count Me In to share their experiences and help accelerate cancer research.

The Drug Repurposing Hub is one of the most comprehensive and up-to-date biologically annotated collections of FDA-approved compounds in the world. Researchers anywhere can explore more than 6,000 drugs in the hub and search for possible new uses for them to jump-start new drug discovery.

In 2021, our sustainability efforts sent more than 80 percent of waste from the Genomics Platform to either a recycling facility or to an incineration plant that generates electricity.

Through Ó³»­´«Ã½'s Scientists in the Classroom program, Ó³»­´«Ã½ researchers visit every 8th grade classroom in Cambridge each year to talk about genetics and evolution.

Every summer, 18 high school students spend six weeks at Ó³»­´«Ã½ working side-by-side with mentors on cutting-edge research.

In November 2022, Ó³»­´«Ã½â€™s Genomics Platform sequenced its 500,000th whole human genome, a mere four years after sequencing its 100,000th.

By the end of 2022, Ó³»­´«Ã½â€™s COVID-19 testing lab had processed more than 37 million tests.

Working with Addgene, Ó³»­´«Ã½ has shared CRISPR genome-editing reagents with researchers at more than 3,200 institutions in 76 countries.

The NeuroGAP-Psychosis project, a collaboration between the Stanley Center for Psychiatric Research and Harvard T.H. Chan School of Public Health to study the genetics of severe mental illness, has recruited more than 42,000 participants in Ethiopia, Kenya, Uganda, and South Africa.

Footer menu

  • Report a concern
  • Contact Us
  • Privacy Policy

© Ó³»­´«Ã½ 2025